HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Akio Abe Selected Research

Type III Secretion Systems

1/2022Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox.
10/2020Transcriptional Downregulation of a Type III Secretion System under Reducing Conditions in Bordetella pertussis.
12/2018Bordetella bronchiseptica Bcr4 antagonizes the negative regulatory function of BspR via its role in type III secretion.
6/2012Iron starvation regulates the type III secretion system in Bordetella bronchiseptica.
2/2011A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium.
4/2008Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties.
6/2004The type III secreted protein BopD in Bordetella bronchiseptica is complexed with BopB for pore formation on the host plasma membrane.
12/2003BopB is a type III secreted protein in Bordetella bronchiseptica and is required for cytotoxicity against cultured mammalian cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Akio Abe Research Topics

Disease

7Infections
10/2020 - 12/2003
5Whooping Cough (Pertussis)
10/2020 - 02/2008
3Hemolysis
01/2022 - 04/2008
2Starvation
06/2012 - 01/2012
2Metabolic Syndrome (Dysmetabolic Syndrome X)
08/2010 - 06/2006
1Intestinal Diseases (Diseases, Intestinal)
01/2018
1Necrosis
01/2016
1Type 2 Diabetes Mellitus (MODY)
08/2010
1With Papillary Renal Neoplasia Papillary Thyroid Carcinoma
05/2010
1Chronic Kidney Failure (Chronic Renal Failure)
10/2006
1Atherosclerosis
06/2006
1Coinfection
10/2005
1Respiratory Syncytial Virus Infections
10/2005
1Thrombocytosis (Thrombocythemia)
10/2005
1Atopic Dermatitis (Atopic Eczema)
05/2004
1Skin Manifestations
05/2004

Drug/Important Bio-Agent (IBA)

8Type III Secretion SystemsIBA
01/2022 - 12/2003
3VaccinesIBA
03/2011 - 02/2008
2AurodoxIBA
01/2022 - 02/2011
2Proteins (Proteins, Gene)FDA Link
10/2020 - 03/2011
2IronIBA
06/2012 - 01/2012
2Pertussis VaccineIBA
05/2010 - 02/2008
2AntigensIBA
05/2010 - 05/2004
2pigment epithelium-derived factorIBA
10/2006 - 06/2006
1DithioerythritolIBA
10/2020
1Reducing AgentsIBA
10/2020
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
10/2020
1Mercaptoethanol (2 Mercaptoethanol)IBA
10/2020
1Tyrosine (L-Tyrosine)FDA Link
01/2018
1Phenylalanine (L-Phenylalanine)FDA Link
01/2018
1Amino AcidsFDA Link
01/2016
1Bordetella Virulence FactorsIBA
01/2012
1PolyketidesIBA
02/2011
1CytokinesIBA
08/2010
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2010
1LeptinIBA
08/2010
1AdiponectinIBA
08/2010
1AdipokinesIBA
08/2010
1pertactinFDA Link
05/2010
1Pertussis ToxinIBA
05/2010
1Uric Acid (Urate)IBA
06/2006
1Interleukin-6 (Interleukin 6)IBA
10/2005
1Thrombopoietin (c-mpl Ligand)IBA
10/2005
1Pharmaceutical PreparationsIBA
05/2004
1Immunoglobulin E (IgE)IBA
05/2004
1Antifungal AgentsIBA
05/2004
1Terbinafine (Lamisil)FDA LinkGeneric
05/2004